HC Wainwright Analysts Raise Earnings Estimates for argenex

argenex SE (NASDAQ:ARGX) – Analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for argenex in a research note issued on Friday, July 24th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $6.51 for the quarter, up from their prior estimate of $6.48. HC Wainwright has a “Buy” rating and a $940.00 price target on the stock. The consensus estimate for argenex’s current full-year earnings is $26.95 per share. HC Wainwright also issued estimates for argenex’s Q1 2027 earnings at $7.57 EPS, Q2 2027 earnings at $8.41 EPS, Q3 2027 earnings at $8.86 EPS and Q4 2027 earnings at $9.53 EPS.

A number of other equities analysts also recently commented on the company. Citigroup increased their price objective on argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Oppenheimer lifted their target price on shares of argenex from $1,014.00 to $1,037.00 and gave the company an “outperform” rating in a research note on Friday. Weiss Ratings downgraded shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Glj Research upgraded shares of argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Finally, Guggenheim raised their price target on shares of argenex from $1,135.00 to $1,185.00 and gave the company a “buy” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,050.50.

argenex Price Performance

Shares of argenex stock opened at $918.22 on Monday. The firm has a market cap of $57.44 billion, a price-to-earnings ratio of 35.26, a P/E/G ratio of 1.21 and a beta of 0.45. argenex has a 52-week low of $587.37 and a 52-week high of $953.58. The stock has a 50-day simple moving average of $868.28 and a 200-day simple moving average of $815.22.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion.

Institutional Investors Weigh In On argenex

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARGX. Sound Income Strategies LLC bought a new stake in argenex during the fourth quarter worth approximately $28,000. Whipplewood Advisors LLC acquired a new stake in shares of argenex in the first quarter worth $28,000. Eastern Bank bought a new stake in shares of argenex during the 2nd quarter worth $32,000. Sunbelt Securities Inc. bought a new stake in shares of argenex during the 3rd quarter worth $36,000. Finally, Axiom Investment Management LLC acquired a new stake in shares of argenex in the first quarter valued at about $50,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.